Skip to main content

DRO2102 / URGUP23077 / Zhang

Basic Study Information

This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also evaluate the effect of lisinopril on urinary symptoms and the impact of lisinopril on biomarkers and their association with urinary symptoms.

Location: Wilmot Cancer Institute

Lead Researcher (Principal Investigator)

Lead Researcher:  Hong Zhang

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email:

Additional Study Details

Return to Search